Tweet
Alps Advisors Inc. cut its position in shares of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) by 26.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,847 shares of the biopharmaceutical company's stock after selling 4,932 shares during the period. Alps Advisors Inc.'s holdings in Madrigal Pharmaceuticals were worth $1,271,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Madrigal Pharmaceuticals by 52.4% during the first quarter. BlackRock Inc. now owns 319,093 shares of the biopharmaceutical company's stock valued at $37,268,000 after purchasing an additional 109,665 shares during the period. Millennium Management LLC grew its position in Madrigal Pharmaceuticals by 2,263.4% in the first quarter. Millennium Management LLC now owns 92,291 shares of the biopharmaceutical company's stock valued at $10,779,000 after acquiring an additional 88,386 shares during the period. Northern Trust Corp grew its position in Madrigal Pharmaceuticals by 12.9% in the first quarter. Northern Trust Corp now owns 73,640 shares of the biopharmaceutical company's stock valued at $8,600,000 after acquiring an additional 8,393 shares during the period. Geode Capital Management LLC grew its position in Madrigal Pharmaceuticals by 50.9% in the fourth quarter. Geode Capital Management LLC now owns 54,299 shares of the biopharmaceutical company's stock valued at $4,984,000 after acquiring an additional 18,319 shares during the period. Finally, Artal Group S.A. bought a new stake in Madrigal Pharmaceuticals in the first quarter valued at $5,256,000. Institutional investors and hedge funds own 43.78% of the company's stock. Get Madrigal Pharmaceuticals alerts:
Shares of NASDAQ:MDGL opened at $238.25 on Friday. The firm has a market capitalization of $3.57 billion, a price-to-earnings ratio of -92.87 and a beta of 1.36. Madrigal Pharmaceuticals Inc has a fifty-two week low of $15.53 and a fifty-two week high of $325.98. Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.18. equities research analysts anticipate that Madrigal Pharmaceuticals Inc will post -2.19 EPS for the current fiscal year.
A number of analysts have weighed in on MDGL shares. Oppenheimer set a $130.00 price target on Madrigal Pharmaceuticals and gave the company a "hold" rating in a research report on Tuesday, May 8th. Cowen reiterated a "buy" rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, May 10th. Zacks Investment Research upgraded Madrigal Pharmaceuticals from a "sell" rating to a "buy" rating and set a $132.00 price target on the stock in a research report on Friday, May 11th. HC Wainwright upped their price target on Madrigal Pharmaceuticals to $178.00 and gave the company a "buy" rating in a research report on Thursday, May 24th. Finally, ValuEngine cut Madrigal Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. Madrigal Pharmaceuticals presently has an average rating of "Buy" and an average target price of $310.29.
In other Madrigal Pharmaceuticals news, insider Rebecca Taub sold 73,526 shares of the business's stock in a transaction on Monday, June 11th. The stock was sold at an average price of $287.46, for a total value of $21,135,783.96. The transaction was disclosed in a document filed with the SEC, which is available at this link . Also, CFO Marc R. Schneebaum sold 10,099 shares of the business's stock in a transaction on Monday, June 11th. The stock was sold at an average price of $287.46, for a total value of $2,903,058.54. The disclosure for this sale can be found here . In the last three months, insiders sold 363,625 shares of company stock worth $104,527,643. Insiders own 56.70% of the company's stock.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ÃŸ-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
See Also: Fundamental Analysis
Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL). Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter 